MARKET WIREReuters • 2h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why ELAB Stock surged +2.72% Today — RQD Quant Desk Flash
$2.64 +2.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.65
PMGC Holdings Inc. (ELAB) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $2.1M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.65 (+0.30%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-9.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELAB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY ELAB SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (28% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$3.08-10.1% Next Q
44
Q2 (-2Q)Grade D$2.77-2.2% Next Q
41
Q3 (-1Q)Grade E$2.71-2.6% Next Q
39
CurrentGrade D-$2.64-8.3% Hist 90D α
36
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ELAB Turnaround Squeeze
While ELAB currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.05) and Max Pain ($2.77) forces dealer call-delta covering toward $1,566.43.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELAB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ELAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ELAB Stock surged +2.72% Today — RQD Quant Desk Flash
PMGC Holdings Inc. (ELAB) surged +2.72% to $2.64, trading at 2% of its 52-week range ($2.51 – $1491.84). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($2.51 – $1491.84) with RSI-14 at 25.9 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.64 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 18.5% gross margin and $0 annual free cash flow.
Live ELAB Headlines & Catalysts
MARKET WIRECNBC • 4h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 4h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 5h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 7h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 7h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 8h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 8h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELAB)
- ✓Walkthrough of ELAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ELAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -89.27%⚡ TESTING RESISTANCE
2026-10-30O $2.64H $2.70L $2.51C $2.64VOL 7.5K
RES: $3.60SUP: $-2.57SMA50: $4.05SMA200: $35.54
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ELAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ELAB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ELAB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ELAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELAB)
Health Care Rank #805 of 1016
⚔️ REVB vs ELAB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ELAB vs. REVB, PPCB, BDRX, SILO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, PMGC Holdings Inc. (ELAB) ranks #805 by composite RQD confidence (36/100, grade D-) and #995 by equity capitalization ($2.1M). Within this direct 5-issuer industry benchmark cohort, ELAB leads on earnings valuation at N/A trailing P/E, while ELAB leads on capital efficiency and profitability with -35.0% ROIC and 31.4% gross margin. REVB currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with ELAB at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ELAB
ACTIVE
PMGC Holdings Inc. | D- | 36/100 | — | 31.4% | -35.0% | +2.72% | $2.1M | Benchmark Subject |
| REVB Revelation Biosciences Inc. | D | 49/100 | — | — | -35.0% | +0.81% | $2.1M | /revb-vs-elab → |
| PPCB Propanc Biopharma Inc. | D- | 36/100 | — | — | -35.0% | 0.00% | $2.2M | /ppcb-vs-elab → |
| BDRX Biodexa Pharmaceuticals plc American Depositary Shs | D | 48/100 | — | — | — | -5.80% | $2.0M | /bdrx-vs-elab → |
| SILO Silo Pharma Inc. | E | 19/100 | — | 38.6% | -35.0% | -6.72% | $2.4M | /silo-vs-elab → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001840563In its most recent audited fiscal period (FY2025, filed 2025-12-31), PMGC Holdings Inc. (ELAB) reported GAAP revenue of $590.1K (N/A vs. FY2024 revenue of $0 , and -65.5% cumulative change since FY2023) , GAAP net income of -$7.7M, operating cash flow of -$5.9M, and free cash flow of -$6.4M (-16.0% YoY). On the balance sheet, ELAB closed FY2025 with $12.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $590.1K | -$7.7M | -$5.9M | -$6.4M | $12.9M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$6.2M | -$5.5M | -$5.5M | $9.0M | — |
| FY2023 (FY) | 2023-12-31 | $1.7M | -$4.3M | -$4.6M | -$4.6M | — | — |
3. ELAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ELAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, PMGC Holdings Inc. (NASDAQ: ELAB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $2.64 (+2.72% 1D, market cap $2.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ELAB ranks #805 in composite RQD confidence.
How does ELAB compare to REVB and PPCB in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELAB carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 31.4%, and ROIC of -35.0%. By comparison, REVB (Revelation Biosciences Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M) and PPCB (Propanc Biopharma Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.2M). Among the 5-stock peer group, ELAB leads on earnings multiple (N/A) while ELAB leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ELAB?
Per ELAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840563), PMGC Holdings Inc. generated $590.1K in revenue, -$7.7M in net income, and -$6.4M in free cash flow against $12.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ELAB trading relative to its 50-day, 200-day, and 52-week technical levels?
ELAB last traded at $2.64 (+2.72% on volume of 6,711 shares), positioning the stock -34.81% below its 50-day simple moving average ($4.05) and -92.57% below its 200-day simple moving average ($35.54). Across its 52-week range of $2.51 to $1,491.84, ELAB sits at the 0.0% percentile with a 14-day RSI of 25.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.31 to $2.97).
ELAB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ELAB stock moving today?
Why ELAB Stock surged +2.72% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.